Item 1A. Risk Factors

There have been no material changes to the risk factors disclosed in Item 1A in our 2022 10-K, except as described below.

We are subject to risks related to our use of generative AI, a new and emerging technology, which is in the early stages of commercial use.

In the second quarter of 2023, we entered into strategic partnerships with leading AI technology companies, enabling enhanced product and service capabilities in generative AI. This technology, which is a new and emerging technology in early stages of commercial use, presents a number of risks inherent in its use, including ethical considerations, public perception, intellectual property protection, regulatory compliance, privacy concerns and data security, all of which could have a material adverse effect on our business, results of operations and financial position. As a result, we cannot predict future developments in AI and related impacts to our business and our industry. If we are unable to successfully adapt to new developments related to, and risks and challenges associated with AI, our business, results of operations and financial position could be negatively impacted.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Common stock repurchases during the three months ended June 30, 2023:

During the three months ended June 30, 2023, we purchased 2,456,257 shares of our common stock in the open market for general corporate purposes, and we withheld 103,325 shares from employees to satisfy estimated statutory income tax obligations related to stock option exercises. The value of the common stock withheld was based on the closing price of our common stock on the applicable exercise dates. There were no unregistered sales of equity securities during the three months ended June 30, 2023.